Radionuclide Therapy for Neuroendocrine Tumours
Cancer Care Ontario aims to provide equitable access to high-quality radionuclide therapy through a Health Canada approved regulatory framework.
Provincial Review of Safety and Access
In 2010, a formal provincial review was conducted with support from the Program in Evidence-Based Care to ensure:
- The most appropriate radiopharmaceuticals are used safely on the right patients
- Neuroendocrine tumour patients who are eligible for radionuclide therapy have equitable access to this treatment in Ontario
Neuroendocrine Tumours Steering Committee
The Neuroendocrine Tumours Steering Committee helps oversee the implementation of the provincial program that ensures patients with neuroendocrine tumours have appropriate access to radionuclide therapy. The committee works with members of the multi-centre provincial treatment group and leaders of the provincial clinical trial to ensure delivery of high-quality care through regional collaboration.
Radionuclide therapy is available through a Health Canada approved clinical trial. The clinical trial will gather evidence on the effects of radionuclide therapy on patients, with the goal of the drugs receiving full approval, through a noticed of Compliance, by Health Canada.
Four Ontario hospitals are providing treatment as part of the clinical trial:
Hamilton Health Sciences
London Health Sciences Centre
Sunnybrook Health Sciences Centre
University Health Network
Multidisciplinary Cancer Conference
The centres share expertise and take part in a provincial multi-centre multidisciplinary cancer conference (MCC). The conference is a forum for clinicians to bring cases for discussion, when additional input is needed, to inform treatment decisions.
To determine if a patient is a candidate for the clinical trial, the clinician may refer the patient’s case to the provincial MCC for review. If the group decides that the patient may be a candidate, the case will be referred to one of the clinical trial sites to be assessed. Only patients who meet the eligibility criteria may receive treatment as part of the clinical trial. For patients who are not candidates, the MCC may propose other treatment options.